Potential Value of PSA Velocity in Prostate Cancer Patients Undergoing Active Surveillance

In the continuing search for ways to identify progression of prostate cancer in patients who are managed by active surveillance, researchers used the U.S. Veterans Affairs health database to assess the value of prostate-specific-antigen (PSA) velocity — the rate at which PSA increases following diagnosis. In this retrospective cohort study, 5300 patients were identified with localized prostate cancer of the lowest grade (International Society of Urologic Pathology grade 1 [Am J Surg Pathol 2016; 40:244]), PSA level ≤10 ng/dL, and no active treatment for at least 1 year following diagnosis. Analyses were adjusted for substantial differences between Black and non-Hispanic white patients in age, chronic medical disease, and socioeconomic param…